Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

38.23USD
16 Nov 2018
Change (% chg)

$0.04 (+0.10%)
Prev Close
$38.19
Open
$38.20
Day's High
$38.99
Day's Low
$37.46
Volume
756,255
Avg. Vol
793,061
52-wk High
$111.36
52-wk Low
$33.52

Latest Key Developments (Source: Significant Developments)

Bioxcel Therapeutics Expands Immuno-Oncology Partnership With Nektar
Monday, 24 Sep 2018 

Sept 24 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS EXPANDS IMMUNO-ONCOLOGY PARTNERSHIP WITH NEKTAR INTO CLINICAL DEVELOPMENT IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - CO AND NEKTAR ARE EXPANDING THEIR ONGOING RESEARCH COLLABORATION INTO A NEW CLINICAL PARTNERSHIP.BIOXCEL THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, CO WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.  Full Article

Nektar Therapeutics Q2 Earnings Per Share $5.33
Wednesday, 8 Aug 2018 

Nektar Therapeutics ::REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 EARNINGS PER SHARE $5.33.Q2 REVENUE $1.088 BILLION VERSUS I/B/E/S VIEW $1.03 BILLION.Q2 EARNINGS PER SHARE VIEW $5.22 -- THOMSON REUTERS I/B/E/S.REVENUE IN Q2 WAS $1.088 BILLION AS COMPARED TO $34.6 MILLION IN Q2 2017.  Full Article

Nektar Therapeutics Announces New Drug Application For NKTR-181 Accepted For Review By FDA
Monday, 30 Jul 2018 

July 30 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION FOR NKTR-181 ACCEPTED FOR REVIEW BY FDA.NEKTAR THERAPEUTICS - NDA IS EXPECTED TO BE ASSIGNED A PDUFA TARGET ACTION DATE OF MAY 28, 2019 BY FDA.  Full Article

Nektar Therapeutics Submits NDA To Treat Chronic Low Back Pain
Thursday, 31 May 2018 

May 31 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS ANNOUNCES SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FDA FOR NKTR-181, A FIRST-IN-CLASS INVESTIGATIONAL OPIOID TO TREAT CHRONIC LOW BACK PAIN IN ADULT PATIENTS NEW TO OPIOID THERAPY.  Full Article

Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
Wednesday, 30 May 2018 

May 30 (Reuters) - Nektar Therapeutics ::SYNDAX AND NEKTAR THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION.NEKTAR- ANNOUNCED NON-EXCLUSIVE, CLINICAL COLLABORATION TO EVALUATE SAFETY, EFFICACY OF NEKTAR'S NKTR-214, IN COMBINATION WITH SYNDAX'S ENTINOSTAT.NEKTAR THERAPEUTICS - COLLABORATION WILL EVALUATE COMBINATION OF ENTINOSTAT WITH NKTR-214 IN PATIENTS WITH PD-1 REFRACTORY MELANOMA.NEKTAR THERAPEUTICS - ADDITIONAL FINANCIAL DETAILS AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Nektar Therapeutics Reports Q1 Loss Per Share $0.60
Thursday, 10 May 2018 

May 10 (Reuters) - Nektar Therapeutics ::REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2018.Q1 LOSS PER SHARE $0.60.Q1 REVENUE $38 MILLION VERSUS I/B/E/S VIEW $35.6 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S.  Full Article

Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Nektar Therapeutics ::NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL EACH MAINTAIN GLOBAL COMMERCIAL RIGHTS TO THEIR RESPECTIVE INVESTIGATIONAL MEDICINES.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL SPLIT COSTS RELATED TO CLINICAL TRIAL.NEKTAR THERAPEUTICS - FIRST TRIAL IS EXPECTED TO START IN SECOND HALF OF 2018.NEKTAR - FIRST TRIAL TO EVALUATE COMBINATION OF EVERY 3-WEEK SCHEDULE OF NKTR-214 WITH ORAL DAILY DOSES OF TAK-659 IN PATIENTS WITH NON-HODGKIN LYMPHOMA.  Full Article

Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​.  Full Article

Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018.NEKTAR THERAPEUTICS - CO WILL PAY TO DAIICHI A $12.5 MILLION TERMINATION PAYMENT AND ALL RIGHTS AND LICENSES GRANTED TO DAIICHI UNDER AGREEMENT.NEKTAR THERAPEUTICS - TERMINATION PAYMENT DOES NOT CHANGE CO'S S 2017 FINANCIAL GUIDANCE, WHICH WAS PROVIDED IN FINANCIAL RESULTS ON NOV 7.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

RPT-BUZZ- U.S. stocks weekly: Rate rout

** S&P 500 sags for second straight week, finishes down 1 pct as bond yields soar